Out-of-Pocket Costs for Chronic Illness Management in High-Deductible Health Plans
8 affiliations
- 1Division of Health Care Policy and Research, University of Colorado School of Medicine, Aurora
- 2RAND Corporation, Santa Monica, California
- 3Department of Health Policy and Management, University of California, Los Angeles
- 4Department of Health Systems, Management and Policy, Colorado School of Public Health, Aurora
- 5Department of Economics, University of Southern California, Los Angeles
- 6Division of Primary Care and Population Health, Stanford University, Palo Alto, California
- 7Department of Medicine, University of California, San Francisco
- 8RAND Corporation, Arlington, Virginia
Abstract
Importance: High-deductible health plans (HDHPs) enroll a substantial share of privately insured Americans and are associated with reduced use of care, even care that is considered medically necessary. However, the magnitude of patient out-of-pocket (OOP) costs required to obtain evidence-based medical care when enrolled in HDHPs remains poorly understood.
Objective: To estimate patient OOP costs required to receive guideline-concordant care for common chronic conditions when enrolled in an HDHP vs a non-HDHP.
Design, Setting, and Participants: This retrospective cohort study used 2022 to 2023 national commercial insurance claims data. Participants included adults aged 18 to 64 years with employer-sponsored insurance and previously diagnosed diabetes, hypertension, or both. To enter the cohort, persons had to have received guideline-concordant care for their chronic illnesses. Data were analyzed from July 2025 to April 2026.
Exposure: Enrollment in an HDHP vs a non-HDHP.
Main Outcomes and Measures: The primary outcome was annual patient OOP costs to receive evidence-based care. Entropy balancing and generalized linear models with geographic fixed effects estimated the mean OOP costs of receiving minimum recommended medical care for diabetes, hypertension, or both in HDHPs and non-HDHPs. Estimates were weighted to ensure that observed costs were representative of the full sample of chronically ill persons.
Results: There were 539 590 adults receiving guideline-concordant care who entered the cohort. After entropy balancing, groups exhibited mean covariate balance, with males representing 57.9% of HDHP enrollees and 57.8% of non-HDHP enrollees, and similar age distributions across groups, with 45.4% of both HDHP and non-HDHP enrollees 55 to 64 years of age. The estimated annual OOP cost for individuals to receive guideline-concordant diabetes care was $153.91 (95% CI, 150.18−157.64) in HDHPs vs $68.06 (95% CI, 66.34−69.78) in non-HDHPs; $128.94 (95% CI, 127.25−130.64) in HDHPs vs $53.89 (95% CI, 53.20−54.58) in non-HDHPs for guideline-concordant hypertension care; and $164.18 (95% CI, 160.93−167.44) in HDHPs vs $100.60 (95% CI, 98.80−102.39) in non-HDHPs for guideline-concordant care for comorbid diabetes and hypertension (all P < .001).
Conclusions and Relevance: In this cohort study of a large, national sample of chronically ill adults with hypertension, diabetes, or both, annual patient costs were 1.6 to 2.4 times as high to receive recommended care in HDHPs vs non-HDHPs, although the magnitude of the difference in OOP costs was relatively small (range, $63.68 to $85.85). Findings provide novel evidence quantifying the magnitude of cost burden experienced by chronically ill patients under various insurance mechanisms and complement prior HDHP studies evaluating health care utilization.
Related
- Medical and non-medical out-of-pocket cost and time burden of COVID-19 illness in U.S. children and adults: a cross-sectional survey study
- Key factors for an equitable health intervention for Black men with low income and chronic illness in a southern state in the United States
- Cross-Cutting Symptom Burden and Health-Related Quality of Life in Hospitalized Patients With Chronic Illness: A Cross-Sectional Study
- Sleep Disturbances and Health-Related Quality of Life in Paediatric Oncology: A Comparative Study with Non-Oncological Chronic Illness and Healthy Peers.
- Out-of-pocket costs and productivity losses associated with influenza illness and caregiving in a household study in the United States, 2024-2025
BibTeX
@article{gidwani2026outofpocket,
title = {{Out-of-Pocket Costs for Chronic Illness Management in High-Deductible Health Plans}},
author = {Risha Gidwani and Zachary Wagner and Steven M. Asch and Veronica Yank and Lane Burgette},
journal = {JAMA Network Open},
year = {2026},
month = oct,
doi = {10.1001/jamanetworkopen.2026.38780},
url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855261},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Out-of-Pocket Costs for Chronic Illness Management in High-Deductible Health Plans
AU - Risha Gidwani
AU - Zachary Wagner
AU - Steven M. Asch
AU - Veronica Yank
AU - Lane Burgette
PY - 2026
DA - 2026/10/13
JO - JAMA Network Open
DO - 10.1001/jamanetworkopen.2026.38780
UR - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2855261
AB - Importance: High-deductible health plans (HDHPs) enroll a substantial share of privately insured Americans and are associated with reduced use of care, even care that is considered medically necessary. However, the magnitude of patient out-of-pocket (OOP) costs required to obtain evidence-based medical care when enrolled in HDHPs remains poorly understood. Objective: To estimate patient OOP costs required to receive guideline-concordant care for common chronic conditions when enrolled in an HDHP vs a non-HDHP. Design, Setting, and Participants: This retrospective cohort study used 2022 to 2023 national commercial insurance claims data. Participants included adults aged 18 to 64 years with employer-sponsored insurance and previously diagnosed diabetes, hypertension, or both. To enter the cohort, persons had to have received guideline-concordant care for their chronic illnesses. Data were analyzed from July 2025 to April 2026. Exposure: Enrollment in an HDHP vs a non-HDHP. Main Outcomes and Measures: The primary outcome was annual patient OOP costs to receive evidence-based care. Entropy balancing and generalized linear models with geographic fixed effects estimated the mean OOP costs of receiving minimum recommended medical care for diabetes, hypertension, or both in HDHPs and non-HDHPs. Estimates were weighted to ensure that observed costs were representative of the full sample of chronically ill persons. Results: There were 539 590 adults receiving guideline-concordant care who entered the cohort. After entropy balancing, groups exhibited mean covariate balance, with males representing 57.9% of HDHP enrollees and 57.8% of non-HDHP enrollees, and similar age distributions across groups, with 45.4% of both HDHP and non-HDHP enrollees 55 to 64 years of age. The estimated annual OOP cost for individuals to receive guideline-concordant diabetes care was $153.91 (95% CI, 150.18−157.64) in HDHPs vs $68.06 (95% CI, 66.34−69.78) in non-HDHPs; $128.94 (95% CI, 127.25−130.64) in HDHPs vs $53.89 (95% CI, 53.20−54.58) in non-HDHPs for guideline-concordant hypertension care; and $164.18 (95% CI, 160.93−167.44) in HDHPs vs $100.60 (95% CI, 98.80−102.39) in non-HDHPs for guideline-concordant care for comorbid diabetes and hypertension (all P < .001). Conclusions and Relevance: In this cohort study of a large, national sample of chronically ill adults with hypertension, diabetes, or both, annual patient costs were 1.6 to 2.4 times as high to receive recommended care in HDHPs vs non-HDHPs, although the magnitude of the difference in OOP costs was relatively small (range, $63.68 to $85.85). Findings provide novel evidence quantifying the magnitude of cost burden experienced by chronically ill patients under various insurance mechanisms and complement prior HDHP studies evaluating health care utilization.
SN - 2574-3805
ER -